Navigation Links
Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease

ical needs. Amicus is currently conducting Phase 2 clinical trials for its two lead compounds, Amigal(TM) for Fabry disease, and Plicera(TM) for Gaucher disease. The company is currently conducting Phase 1 trials with AT2220 for the treatment of Pompe disease.

CONTACT: Corporate: Matthew Patterson for Amicus Therapeutics,+1-609-662-2000; or Media: Dan Budwick for BMC Communications Group,+1-212-477-9007, Ext. 14

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3

Related medicine technology :

1. Amicus Therapeutics Presents Positive Results From Phase 1 Clinical Studies of Plicera for Gaucher Disease
2. Amicus Therapeutics Presents Data From Preclinical and Phase 1 Studies of Amigal for Fabry Disease
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer

Post Your Comments:
(Date:11/25/2009)...v.25/PRNewswire-FirstCall/--Abaxis,Inc.(Nasdaq: AB...carebloodanalysissystems,announcedtodaythatClintSe...tatthe21stAnnualPiperJaffrayHealthCareConferenceon...willbeheldattheNewYorkPalaceHotelinNewYorkCity. ,...sandmarketsportablebloodanalysissystemsforuseinany...
(Date:11/25/2009)....25/PRNewswire/--CempraPharmaceuticalsInc.todayann...ecutiveofficer,willpresentatthePiperJaffray21stAnn...9,atTheNewYorkPalaceHotelinNewYorkCity.Dr.Fernande...bioticclinicalprogramsforthetreatmentofdrug-resist...aceuticals ,, Foundedin2006,CempraPharmaceutic...
(Date:11/25/2009)...SYDNEY,Nov.25/PRNewswire-FirstCall/--HeartWareInte...vatorandprovideroflessinvasive,miniaturizedcircula...ofadvancedheartfailure,todayannouncedthatitissched...erJaffrayHealthCareConferenceat8:00amESTonWednesda...orkPalaceHotel,December1-2. ,, Alivewebcastofth...
Breaking Medicine Technology:Pre clinical Data Show OrbusNeichs Combo Bio engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies 5039 1Pre clinical Data Show OrbusNeichs Combo Bio engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies 5039 2Pre clinical Data Show OrbusNeichs Combo Bio engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies 5039 3SPIRIT IV trial shows everolimus stent sets new standard for event free survival 58174 1SPIRIT IV trial shows everolimus stent sets new standard for event free survival 58174 2Depression and anxiety disorders of adolescents are not the same thing 10069 1
...of research reflects depth and breadth of, collab...w treatments for diverse fo...act of Zometa(R), the leading IV, bisphosphonate, ...t cancer, - Four oral sessions to feature RAD001,...OR, including first results of RECORD-1 study in r...
...ns demonstrated in Blacks, Hispanics/Latinos, Peop...duals, PARSIPPANY, N.J., May 15 Daiichi Sankyo, ...erican Society of,Hypertension,s Twenty- Third Ann...emonstrated that the powerful combination drug AZO... and effectively helped,patients across several ma...
Other Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7
(Date:11/25/2009)...,Nov.25/PRNewswire-USNewswire/--TheBlackAIDSInstit...executiveleadershipfor2010. ,, ThenewBoardMembe...publicpolicy,law,finance,governmenthealthprograms,...comesfromawiderangeofpersonalbackgroundsincludingb...thHIVthemselves,andrepresentingmultipleagegroups. ...
(Date:11/25/2009)... found evidence of a statistically significant sur...ts whose estrogen receptor (ER)-positive tumors ha...erine-118 (ER-alpha S118-P), according to a brief ... Journal of the National Cancer Institute . , Ap... to tamoxifen. Preclinical studies have shown that...
(Date:11/25/2009)... used to fight rheumatoid arthritis, could help ne... WEDNESDAY, Nov. 25 (HealthDay News) -- A drug com...umatoid arthritis now also shows some promise in h...es. , The drug, rituximab (Rituxan), helped pat...en though the disease had destroyed some of their ...
(Date:11/25/2009)...ote, CDC sees few signs of trouble with the H1N1 v...ay News) -- The ongoing H1N1 swine flu pandemic ma...s among younger patients, a U.S. health official s...serious pneumococcal infections around the country...ter for Immunization and Respiratory Diseases at t...
(Date:11/25/2009)... -- A cancer vaccine carried into the body on a ca...e first to successfully eliminate tumors in mammal...ence Translational Medicine . , The new approach...arvard University, uses plastic disks impregnated ...he skin to reprogram the mammalian immune system t...
Breaking Medicine News(10 mins):Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 2Health News:Swine Flu Tied to Rise in Pneumonias Among Young 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 4Health News:Implant-based cancer vaccine is first to eliminate tumors in mice 2
...ost common surgical procedures performed worldwide... called computed tomography can be used to predict...to a new study. Researchers examined 105 patie...ity of acute appendicitis. The study showed CT, wh...
...ffecting more than 2 million people worldwide and ...cuits // of the brain that result in seizures. Mor...e-free by taking medications. Researchers say a...common form of the disorder. Typically, about 80 p...
...ting active can help elderly patients who have tro...// 12 healthy adults between the ages of 67 and 86...m consisted of 30 minutes of exercise followed by ...ticipants first taking part in one of the time per...
...n relief and improves function for people with ost... complement to Normal care. This study was funded ...native Medicine (NCCAM) and the National Institute...ngest and largest randomized, controlled phase III...
... number of countries where iodine deficiency is a ...O Study on a new global report on iodine status.//...as worked well. The number of countries where iodi...lopment of people worldwide, particularly preschoo...
... that for those suffering form asthma, the key to ...earchers conducted a study to look at the connecti...rs. It was found that the higher incidence of asth...l for life on earth because it absorbs the destruc...
Other Medicine News:Health News:Acupunture relieves pain and improves function in knee Osteoarthritis 2Health News:Acupunture relieves pain and improves function in knee Osteoarthritis 3Health News:WHO hopes to wipe away Iodine deficiency diseases by 2005 2
Max-Rom Acetabular Liners
Cofield 2 Total Shoulder System
Integrated Shoulder System
...index. A/P and lateral fins with holes for suture ...al hole, humeral / glenoid diametral curvature mis...ugh textured proximal surface to provide enhanced ...esistance in cement, six stem sizes, fifteen head ...
Medicine Products: